Study Supports High Intensity Exercise to Improve Muscle Condition in MS Patients
A new study recently published in the journal PLOS ONE revealed that high intensity exercise is safe…
Articles by Patricia Silva, PhD
Biogen to Present New Data at Upcoming ECTRIMS 2015 Congress on MS Therapies, Including TECFIDERA
Biogen, a biotechnology company focused on innovative therapies for autoimmune disorders, neurodegenerative diseases and hematological conditions, recently announced that…
FDA Accepts New Drug Application for Osmotica Pharmaceutical’s Ontinua ER for Spasticity in Multiple Sclerosis
Osmotica Pharmaceutical Corp. recently announced…
National MS Society Provides Update on Wellness for Multiple Sclerosis Patients
According to the National Multiple Sclerosis Society (NMSS), a high priority for people with multiple sclerosis (MS) is to achieve…
Teva’s COPAXONE Approved in Japan for the Prevention of Relapse Remitting Multiple Sclerosis
Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions, recently announced that the…
Natalizumab Reported To Be a Safe and Effective Therapy for Pediatric Multiple Sclerosis
A new study recently published in the journal BMC Neurology revealed that natalizumab (TYSABRI) is a safe…
FDA Approves BETACONNECT Autoinjector for BETASERON Delivery
Bayer HealthCare is pleased to announce the US Food and Drug Administration (FDA) has granted the approval of BETACONNECT, a first-of-its-kind…
Could Genentech’s Ocrelizumab Become the First Effective Primary Progressive MS Therapy?
Genentech, a leading biotechnology company and member of the Roche Group, recently announced promising results on a pivotal Phase…
EMD Serono To Present New Data on Rebif, a Therapy for RRMS, at Upcoming ECTRIMS Congress
EMD Serono, the subsidiary of Merck KGaA in the United States, recently announced that it will present new data…
Kessler Foundation Researchers Report BICAMS Can Predict Performance of Everyday Life Activities in Multiple Sclerosis Patients
Kessler Foundation researchers recently reported that the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is able to predict the…
Possible JC Virus Vaccination Offers Important Implications for MS Treatment
Two studies recently published in the journal Science Translational Medicine, revealed a possible new vaccine treatment for…
Medical Marijuana Use for Pain Relief in Medical Conditions like MS and AIDS Explored in New Nature Article
Cannabis is a plant that can be used in a wide range of settings such as medical purposes, a source of fiber…
New Brain Cell Interaction Study Technique Could Impact MS Research
A study led by researchers from the University of Buffalo recently reported the development of a new method to study…
Clinical Benefit of Relapsing-Remitting Multiple Sclerosis Therapies Highlighted in Review
A review study recently published in the journal Cochrane Database of Systematic Review (CDSR) focused on the…
Review Explores Factors that Influence Quality of Life in Patients with Multiple Sclerosis
In a recent review published in the European Journal of Neurology, A. P. Lysandropoulos from the University…
Fingolimod (Gilenya) Found to Be an Effective Multiple Sclerosis Therapy for Up to Three Years of Treatment
An encouraging new analysis reveals that fingolimod is an effective multiple sclerosis (MS) therapy for a treatment period of up to three years.
MS Views and News Reaches Two Locations For the First Time in October
Non-profit, MS News and Views (MSVN), which works nationally to increase education and knowledge about multiple sclerosis…
Pregnancy-Associated Issues in Multiple Sclerosis Patients Highlighted in New Review
A study recently published in the European Journal of Neurology reviewed some of the issues associated with…
Review on Teriflunomide (AUBAGIO), an Oral Therapy for Relapsing Multiple Sclerosis
A review recently published in the journal Clinical Therapeutics focused on teriflunomide as a treatment for patients…
Natalizumab Improves the Neurological Condition of Multiple Sclerosis Patients
Results from a recent Brazilian study, published in the journal Arquivos de Neuro-Psiquiatria, revealed that natalizumab is…
Aphios Awarded Grant for Cannabinoid Production To Develop Therapeutic Agent for MS
Aphios Corporation, a green biotechnology company based in Massachusetts that uses environmentally sustainable technologies, recently announced it was awarded the…
MS Patients and Healthcare Providers Report Success of MSdialog App in Tracking Disease
An international research team recently reported that the web-based MSdialog app is being adopted by both multiple sclerosis (MS) patients and healthcare…
Gut Microbiota Imbalance Discovered in Multiple Sclerosis Patients
A new study recently published in the journal PLOS One revealed that multiple sclerosis (MS) patients have…
Merck Prepares to File for European Marketing Authorization for Cladribine Tablets as a Multiple Sclerosis Therapy
Merck recently reported its intention to file for European registration of its product candidate for relapsing multiple sclerosis – Cladribine, a…
Biogen Obtains Exclusive Rights Over Promising MT-1303 Drug for Autoimmune Diseases, Multiple Sclerosis
Biogen recently announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), a research-driven pharmaceutical company based in Japan, to…
Mortality and Comorbidity Rates Found Higher in MS Patients, Study Finds
A recently published study in the journal Multiple Sclerosis and Related Disorders found notably higher mortality and comorbidity…
Smoking Can Accelerate Disease Progression in Patients with Multiple Sclerosis
A new study entitled “Effect of Smoking Cessation on Multiple Sclerosis Prognosis” recently revealed that smoking by…
Mental Visual Imagery Strategy Can Improve Neuropsychological Functions in RRMS Patients
A new study published in the journal Restorative Neurology and Neuroscience revealed that multiple sclerosis (MS) patients…
Obstructive Sleep Apnea Found To Contribute to Blood–Brain Barrier Breakdown Experienced By MS Patients
In a recent study published in the Journal of Neuroimaging, a team of researchers from the UCLA have…
Cryoport, Inc. to Supply Opexa’s MS and NMO Immunotherapy Studies with Cryogenic Logistics Solutions
Cryoport, Inc., a leader in providing advanced cryogenic logistics solutions for the life sciences industry, has just announced it will be…